Single cell genome engineering
Combining the power of CRISPR with FluidFM®
In the 21st century, the genomic revolution is dawning and with it the way biomedical research is performed. Whole genome sequencing is affordable and therefore, the causes of common genetic diseases become known.
With the advent of the CRISPR/Cas system, cell line engineering to introduce precise modifications into genomes is taking the center stage in modern biomedical research. However, to turn this genomic information and the ability to modify genomes into curing diseases, several obstacles must be cleared. Cell line engineering is still hampered by inefficient delivery of genome editing entities, the danger of mutations in unrelated genomic regions and low efficiencies for precise editing by homologous recombination.
To address these hurdles, we combine CRISPR based genome engineering with our FluidFM® technology. By injecting the genome editing entities directly into the nucleus of a target cell, we circumvent the delivery barrier. Further, the controlled delivery of CRISPR ribonucleic protein complexes to the nucleus of the target cell will minimize the probability of off-target editing and enhance homologous recombination by co-injecting HDR templates. In addition, our single cell approach avoids the tedious selection process and reduces the material costs to a minimum.
In summary, using FluidFM technology to perform single cell genome engineering will improve the quality and the speed, and reduces the costs of cell line development projects in academic and industrial biomedical research.
Key learning points:
What is FluidFM® and how can it be applied to cell line engineering
True single cell genome engineering: the power of the bottom-up approach
High quality monoclonal cell lines by reducing off-target editing and avoiding the tedious selection process
Cut the cost by using minimal amounts of reagents and cells
Speed up the process by staring with a single cell
About the speaker
Dr. Tobias Beyer
CSO / Senior Cell Biologist,
Cytosurge AG
Dr. Tobias Beyer obtained his PhD in Cell Biology at ETH Zurich. After a postdoctoral fellowship at the LTRI in Toronto, he joined ETH Zurich as junior group leader (Groups of Prof. Wutz and Prof. Corn). Here, he combined his expertise in cell biology, cell signaling, and embryonic stem cells with genome engineering using the CRISPR/Cas9 technology. At Cytosurge, Dr. Beyer identifies and develops applications for the FluidFM OMNIUM.